VivoSeq
Hematology

Sickle Cell Crisis

1

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Sickle Cell Crisis is an early-stage landscape with 1 program across 0 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

33/100

Attrition Rate

40/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Sufentanil

Leaf Vertical Inc.

Approved
No programs

Analysis

Trial Status

5

clinical trials

Unknown status2 · 40%
Terminated2 · 40%
Completed1 · 20%

Clinical Trials

Trial Activity

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis
Unknown status·—·Phase 2·NCT04614610·100 enrolled
Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department
Terminated·—·N/A·NCT02417298·12 enrolled
Pilot Study of Fructose for Sickle Cell Crisis
Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00004797·20 enrolled
Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis
Unknown status·IInstituto Estadual de Hematologia Arthur de Siqueira Cavalcanti·Phase 2·NCT03062501·30 enrolled
Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults.
Terminated·UUniversity Hospital, Bordeaux·Phase 3·NCT04076748·115 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)